By The Science Advisory Board staff writers
August 16, 2022 — The Mayo Clinic and biotech company National Resilience have announced a strategic collaboration in biomanufacturing to deliver novel biotherapeutics for rare and complex conditions, with a focus on therapies derived from biologics for use in medicines.
Under the partnership, National Resilience will collaborate with Mayo’s Center for Regenerative Medicine in Two Discovery Square within the research corridor of the Destination Medical Center economic development initiative in Rochester, Minn., according to the announcement.
The two organizations “will build embedded process and analytical development labs, as well as quality control labs” allowing for “closer proximity and collaboration to jointly develop and progress cell therapies and other advanced modalities into clinical care.”
In addition to providing cell and gene products needed for biomanufacturing early-stage therapeutics, the goal is to attract biotech companies interested in sponsoring clinical trials at Mayo Clinic for novel regenerative biotherapeutics.
“Mayo is making significant investments in facilities to create the world’s most advanced and innovative ecosystem for the development, manufacture, and delivery of biotherapeutics. We are seeking to build a community of innovators to explore ideas, develop new products and create thriving biotherapeutic companies,” Julie Allickson, PhD, the Michael S. and Mary Sue Shannon Family Director of Mayo Clinic’s Center for Regenerative Medicine, said in a statement.
